CAR therapies
In Brief This Week: Carisma Therapeutics, Proteomedix, American Cancer Society
News items for the week of Sept. 20, 2021.
Chinese Regulators Approve JW Therapeutics' CAR T-Cell Therapy for Large B-Cell Lymphoma
Shanghai-based JW's relma-cel is the second CAR T-cell therapy to be approved by China's National Medical Products Administration.
Innovative Cellular Therapeutics Gets FDA Clearance to Start Phase I Trial of CAR T-Cell Therapy in US
With the agency's permission, the company will start a Phase I trial of GCC19CART in colorectal cancer patients next year.
The autologous CAR T-cell therapy P-PSMA-101 demonstrated anti-tumor activity in nine metastatic castrate-resistant prostate cancer patients based on PSA levels.
BioCure Technology to Develop ROR1-Targeted CAR T-Cell Therapy
The company will develop a novel CAR T-cell therapy platform, focusing on the chronic lymphocytic leukemia and solid tumor markets.
Aug 6, 2021
Jul 28, 2021
Bristol Myers Squibb Q2 Revenues Grow 16 Percent
Jul 21, 2021